Study of ICP-488 for Primary Sjögren's Syndrome
Part of Immune system & allergy clinical trials.
This study tests an investigational drug called ICP-488 for people with primary Sjögren's syndrome (the main form, not caused by other conditions). The goal is to see if the drug can help control symptoms better than a placebo. Participants must have active disease and stable treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with Sjögren's syndrome for at least 6 months but no more than 5 years.
- Your disease activity is moderate to high (a score of 5 or more on a standard Sjögren's activity scale).
- You have a positive blood test for anti-SSA/Ro antibodies (a common marker in Sjögren's).
- Your current Sjögren's treatment plan (if any) has been stable for at least 4 weeks, and you are willing to continue it unchanged during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether iguratimod improves symptoms in people with primary Sjögren’s syndrome, and checks how safe it is. It focuses on people with confirmed disease markers (anti-SSA/Ro-60) and ongoing dry eyes and dry mouth.
This trial tests an experimental drug, IMVT-1402, in adults with primary Sjogren's disease who have moderate to severe symptoms. The goal is to see if it can reduce disease activity safely.
This study looks at an immune reaction (called anti-Ro/SSA IgE) to see how active primary Sjögren’s disease is. It may help doctors better understand what’s driving symptoms and activity levels over time.
This study follows adults with primary Sjögren’s syndrome. It may help researchers understand the condition better by using information from people who have already joined the earlier ASSESS study.
This study tests a new drug called CM336 for people with primary Sjögren's syndrome (an autoimmune disease affecting salivary and tear glands). The drug is designed to help reduce disease activity in patients who haven't responded well to previous treatments.
This study tests an investigational drug called ESG206, which targets a protein on immune cells, to see if it can safely reduce symptoms of primary Sjögren's syndrome. It is for people whose Sjögren's is not caused by another disease and who have active symptoms.
Hear when a new Primary Sjögren's Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.